Producer
Fujian Southeast Asia Biotechnology Co., Ltd.
Chinese pharmaceutical and biotechnology company (Fuzhou, Fujian Province); major paclitaxel and docetaxel API producer operating extraction and semi-synthesis facilities in Fujian Province. Sources 10-DAB from Taxus chinensis plantations in Yunnan and Fujian and converts via semi-synthesis to paclitaxel API for Chinese finished-dose oncology manufacturers and for export to Asian markets. Representative of the fragmented Chinese paclitaxel API industry where multiple mid-sized provincial manufacturers collectively hold 70-80% of global API supply.
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input Fujian Southeast Asia Biotechnology Co., Ltd. supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Fujian Southeast Asia Biotechnology Co., Ltd. makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Paclitaxel & Docetaxel API
75%Botanical Extraction (10-DAB)
20%Other Oncology APIs
5%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2024
Fujian Southeast Biotech's paclitaxel semi-synthesis depends on 10-DAB harvested from Chinese yew plantations in Yunnan Province — the same mountain forests that also supply traditional Chinese medicine (TCM) botanical materials for a completely separate market. Taxus chinensis bark and needles are processed both for 10-DAB (paclitaxel precursor, pharmaceutical market) and for TCM preparations (traditional medicine market). A policy change affecting Chinese yew plantation management or harvesting regulations would simultaneously impact the paclitaxel supply chain (global cancer treatment) and the TCM supply chain (Chinese domestic traditional medicine) — two regulatory worlds rarely modeled as sharing a common botanical raw material dependency.
Fujian Southeast Asia Biotechnology ↗Origin2023
Fujian Southeast Asia Biotechnology is located in Fuzhou, Fujian Province — a coastal province with a long history of chemical and pharmaceutical manufacturing, and part of the broader Fujian-Yunnan supply chain for Chinese yew (Taxus chinensis) botanical materials. The company sources 10-DAB (10-deacetylbaccatin III), the semi-synthesis precursor for paclitaxel production, from Yunnan Province yew plantations, then semi-synthesizes it into pharmaceutical-grade paclitaxel API at its Fujian facilities. This supply chain runs from Yunnan highland yew forests to Fujian coastal pharmaceutical plants to global generic drug manufacturers — entirely within China.
Fujian Southeast Asia Biotechnology ↗